1. ALLA AKTIER
  2. NYHETER
  3. VÄSTRA HAMNEN CORP. FINANCE

Västra Hamnen Corp. Finance

Nyheter Västra Hamnen Corp. Finance Nyheter alla bolag

CombiGene: Strategic consequences after CG01

  • Implementing cost savings and new priorities
  • New propositions from the main shareholder
  • Our revised fair value estimate is SEK 8.27 (12.19) per share

In our previous analysis, CombiGene was focused on outlicensing the epilepsy project CG01 again after reaching a return agreement with Spark Therapeutics. The company was also focused on developing the COZY programme for chronic pain. After evaluating the status of CG01, CombiGene decided to end the project and prioritise the COZY programme, with emphasis on the gene therapy COZY02. The company will also implement cost savings to prolong its financial runway. In Västra Hamnen’s webcast, CEO Peter Ekolind explained the reasons behind these decisions. Shortly after the webcast, the company’s largest shareholder proposed strategic changes, which shareholders will vote on in December. After a review, our estimated value is 8.27 SEK per share.

The full report is available here

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Datum 2024-11-11, kl 13:38
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!